The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study

BACKGROUND: Treatment goals for patients with systemic lupus erythematosus (SLE) include minimising disease activity and reducing the risk of flares. Although belimumab is effective at reducing disease activity and risk of severe flares, it was previously unknown what the clinical effects were upon...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Sang-Cheol, Bass, Damon L., Chu, Myron, Curtis, Paula, Dimelow, Richard, Harvey, Laurence, Ji, Beulah, Kurrasch, Regina, Muzaffar, Saima, Punwaney, Raj, Roth, David A., Song, Yeong-Wook, Xie, Wendy, Zhang, Fengchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848800/
https://www.ncbi.nlm.nih.gov/pubmed/35172878
http://dx.doi.org/10.1186/s13075-022-02723-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848800/
https://www.ncbi.nlm.nih.gov/pubmed/35172878
http://dx.doi.org/10.1186/s13075-022-02723-y

Ejemplares similares